ProKidney (NasdaqCM:PROK) has had its one-year price target revised to $6.85 per share, reflecting a 15.10% increase from the previous estimate of $5.95 set on December 3, 2025. This new target represents a potential upside of 188.97% from the latest closing price of $2.37 per share. Analyst targets range from a low of $1.01 to a high of $12.60 per share.
Institutional interest in ProKidney has also grown, with 121 funds reporting positions, an increase of 12.04% from the last quarter. Total shares owned by these institutions surged by 179.68% over three months, now totaling 37,294,000 shares. The average portfolio weight dedicated to ProKidney is 0.02%, up 165.56%. The stock’s put/call ratio stands at 0.31, suggesting a bullish outlook among investors.
Key institutional holders include Suvretta Capital Management with 12,341,000 shares (8.72% ownership), Bleichroeder with 2,000,000 shares (1.41%), and Millennium Management with 1,956,000 shares (1.38%). Fidelity Small Cap Index Fund increased its holdings by 7.69%, now owning 1,130,000 shares (0.80%).
